Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Sep 30, 2019
Posted in: Investor updates

Home » Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Sep 30, 2019
Posted in: Investor updates

Imagion Biosystems Limited has given notice under section 708A(5)(e) of the Corporations Act 2001.
Read the notice.

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

June 3, 2026

Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)

Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent

January 31, 2026

Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has

Quarterly Activities Report and Appendix 4C – December 2025

January 28, 2026

Key Highlights: Manufacturing and Testing of MagSense® HER2 Imaging Agent Completed, Paving Way for IND Submission Q1 2026 Wayne State University Collaboration for MRI Optimization

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Related Articles

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent

Quarterly Activities Report and Appendix 4C – December 2025

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list